BRAf inactivation drives aneuploidy by deregulating CRAF

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8475-8486

  Kamata, Tamihiro ^a   Hussain, Jahan ^a   Giblett, Susan ^a   Hayward, Robert ^b   Marais, Richard ^b   Pritchard, Catrin ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; B RAF KINASE; CRAF PROTEIN; GENE PRODUCT; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANEUPLOIDY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL CULTURE; CELL GROWTH; CELL IMMORTALIZATION; CHROMOSOMAL INSTABILITY; EMBRYO; ENZYME INACTIVATION; FIBROBLAST; GENE MUTATION; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; TUMOR GROWTH;

ANEUPLOIDY; ANIMALS; CELL AGING; CELLS, CULTURED; CHROMOSOMAL INSTABILITY; EMBRYO, MAMMALIAN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SPLEEN; TNF RECEPTOR-ASSOCIATED FACTOR 3;

EID: 78449292368     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0603     Document Type: Article

References (41)

1. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875-85.
2. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-65.
3. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-9.
4. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
6. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
7. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005;20:963-9.
8. Johnson LN, Lowe ED, Noble ME, Owen DJ. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett 1998;430:1-11.
9. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
10. Mercer K, Giblett S, Green S, et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 2005;65: 11493-500.
11. Noble C, Mercer K, Hussain J, et al. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell 2008;31:862-72.
12. Jat PS, Noble MD, Ataliotis P, et al. Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc Natl Acad Sci U S A 1991;88:5096-100.
13. Kamata T, Kang J, Lee TH, Wojnowski L, Pritchard CA, Leavitt AD. A critical function for B-Raf at multiple stages of myelopoiesis. Blood 2005;106:833-40.
14. Hüser M, Luckett J, Chiloeches A, et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J 2001;20:1940-51.
15. Schwenk F, Baron U, Rajewsky K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 1995;23:5080-1.
16. Wojnowski L, Zimmer AM, Beck TW, et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet 1997;16:293-7.
17. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 2002;244: 305-18.
18. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
19. Niault T, Sobczak I, Meissl K, et al. From autoinhibition to inhibition in trans: the Raf-1 regulatory domain inhibits Rok-α kinase activity. J Cell Biol 2009;187:335-42.
20. Narumiya S, Yasuda S. Rho GTPases in animal cell mitosis. Curr Opin Cell Biol 2006;18:199-205.
21. Ehrenreiter K, Piazzolla D, Velamoor V, et al. Raf-1 regulates Rho signaling and cell migration. J Cell Biol 2005;168:955-64.
22. Piazzolla D, Meissl K, Kucerova L, Rubiolo C, Baccarini M. Raf-1 sets the threshold of Fas sensitivity by modulating Rok-α signaling. J Cell Biol 2005;171:1013-22.
23. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006;66:9483-91.
24. Sutor SL, Vroman BT, Armstrong EA, Abraham RT, Karnitz LM. A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf. J Biol Chem 1999;274:7002-10.
25. V600E induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells. Cancer Res 2010;70:675-84.
26. Available from: http://www.sanger.ac.uk/genetics/CGP/cosmic.
27. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113-30.
28. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9.
29. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
30. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol 2006;18:658-67.
31. Williams BR, Prabhu VR, Hunter KE, et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 2008;322:703-9.
32. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 2009;10: 478-87.
33. Baker DJ, Jeganathan KB, Cameron JD, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet 2004;36:744-9.
34. Schliekelman M, Cowley DO, O'Quinn R, et al. Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. Cancer Res 2009;69:45-54.
35. Li M, Fang X, Wei Z, York JP, Zhang P. Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice. J Cell Biol 2009;185:983-94.
36. Sotillo R, Hernando E, Díaz-Rodríguez E, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007; 11:9-23.
37. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008;14:111-22.
38. Thompson SL, Compton DA. Examining the link between chromosomal instability and aneuploidy in human cells. J Cell Biol 2008; 180:665-72.
39. Cimini D, Howell B, Maddox P, Khodjakov A, Degrassi F, Salmon ED. Merotelic kinetochore orientation is a major mechanism of aneuploidy in mitotic mammalian tissue cells. J Cell Biol 2001;153:517-27.
40. Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, Rosner MR. Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell 2006;23:561-74.
41. Bakhoum SF, Thompson SL, Manning AL, Compton DA. Genome stability is ensured by temporal control of kinetochore-microtubule dynamics. Nat Cell Biol 2009;11:27-35.